Trial Outcomes & Findings for Allofit® IT With HXPE in Total Hip Arthroplasty (NCT NCT03672929)

NCT ID: NCT03672929

Last Updated: 2026-01-27

Results Overview

The objective of this study is implant survival at 10 years which is assessed by revision of the the study device. Survivorship at 10 years was defined as cases that had the implant still in place at 10 years.

Recruitment status

COMPLETED

Target enrollment

197 participants

Primary outcome timeframe

10 years post-surgery

Results posted on

2026-01-27

Participant Flow

Enrollment for this study was initiated in 2011 and was completed in 2017. Medizinische Universitat Wien, Universitatsklinik fur Orthopadie, Austria enrolled 41 patients, CHU de Nantes - Site Nord, France enrolled 36 patients, Kliniken Dr. Erler GmbH, Germany enrolled 50 patients, Orthopadie El Masry, Germany enrolled 40 patients and HUA Santiago enrolled 30 patients

Enrollment for this study was initiated in 2011 and was completed in 2017 with 197 patients enrolled in five participating study centers. One site which enrolled 30 patients is inactive since a long time an only has data up to 1-year Post-OP.

Unit of analysis: implants

Participant milestones

Participant milestones
Measure
Patients Who Received the Allofit IT With HXPE
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
Overall Study
STARTED
197 197
Overall Study
COMPLETED
98 98
Overall Study
NOT COMPLETED
99 99

Reasons for withdrawal

Reasons for withdrawal
Measure
Patients Who Received the Allofit IT With HXPE
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
Overall Study
Death
13
Overall Study
Lost to Follow-up
32
Overall Study
Withdrawal by Subject
18
Overall Study
Adverse Event
3
Overall Study
Surgery with the device never took place
3
Overall Study
Inactive site
30

Baseline Characteristics

The gender for 2 participants is not available

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Patients Who Received the Allofit IT With HXPE
n=197 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
Age, Continuous
63.4 years
STANDARD_DEVIATION 9.2 • n=197 Participants
Sex: Female, Male
Female
104 Participants
n=195 Participants • The gender for 2 participants is not available
Sex: Female, Male
Male
91 Participants
n=195 Participants • The gender for 2 participants is not available
Region of Enrollment
Austria
41 participants
n=197 Participants
Region of Enrollment
France
36 participants
n=197 Participants
Region of Enrollment
Germany
90 participants
n=197 Participants
Region of Enrollment
Spain
30 participants
n=197 Participants
BMI
28.0 kg/m²
STANDARD_DEVIATION 4.7 • n=196 Participants • 1 patient does not have information on weight

PRIMARY outcome

Timeframe: 10 years post-surgery

Population: All study patients

The objective of this study is implant survival at 10 years which is assessed by revision of the the study device. Survivorship at 10 years was defined as cases that had the implant still in place at 10 years.

Outcome measures

Outcome measures
Measure
Patients Who Received the Allofit IT With HXPE
n=197 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
Survival of the Implant System
89 participants

SECONDARY outcome

Timeframe: 10 years post-surgery

Population: 33 complications involved the study hip

Safety of the system will be assessed by monitoring the frequency and incidence of adverse events.

Outcome measures

Outcome measures
Measure
Patients Who Received the Allofit IT With HXPE
n=197 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
Safety of the Implant System
33 complications

SECONDARY outcome

Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 Year

Population: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different

The Harris Hip Score (HHS) is an outcome measure that includes a series of questions answered by the patient and physical examinations recorded by a qualified health care professional. The HHS covers four domains: pain (one item, 0-44 points), function and functional activities (seven items, 0-47 points), absence of deformity (one item, 0-4 points) and range of motion (one item, 0-5 points). To obtain a final score, the points are summed. The outcome score can be categorized as Excellent: 90-100; Good: 80-90; Fair: 70-80; Poor: \< 70

Outcome measures

Outcome measures
Measure
Patients Who Received the Allofit IT With HXPE
n=185 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
Harris Hip Score (HHS)
Pre-Op
51.5 score on a scale
Standard Deviation 16.5
Harris Hip Score (HHS)
6 months
92.3 score on a scale
Standard Deviation 10.0
Harris Hip Score (HHS)
1 Year
94.4 score on a scale
Standard Deviation 10.2
Harris Hip Score (HHS)
2 Year
97.1 score on a scale
Standard Deviation 6.0
Harris Hip Score (HHS)
3 Year
96.6 score on a scale
Standard Deviation 6.9
Harris Hip Score (HHS)
5 Year
96.3 score on a scale
Standard Deviation 8.1
Harris Hip Score (HHS)
7 Year
93.0 score on a scale
Standard Deviation 12.6
Harris Hip Score (HHS)
10 Year
96.3 score on a scale
Standard Deviation 7.8

SECONDARY outcome

Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 Year

Population: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different

The EQ-5D-3L is a standardized instrument widely used to measure health status. It is a self-reported assessment about the patient's quality of life composed of two parts: a questionnaire and a visual analogue scale (VAS). The questionnaire includes five dimensions referring to mobility, self-care, daily activities,pain/discomfort, and anxiety/depression. Each question can be answered in three ways/levels indicating no problems, some problems, and extreme problems. In the derived EQ-5D-3L score, the highest score is 1 and the lowest score is -0.594;negative numbers correspond to a self-assessed health state worse than being dead. Higher scores mean a better outcome.

Outcome measures

Outcome measures
Measure
Patients Who Received the Allofit IT With HXPE
n=193 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
EQ-5D-3L Score
Pre-Op
0.4 score on a scale
Standard Deviation 0.3
EQ-5D-3L Score
6 months
0.9 score on a scale
Standard Deviation 0.2
EQ-5D-3L Score
1 Year
0.9 score on a scale
Standard Deviation 0.2
EQ-5D-3L Score
2 Year
0.9 score on a scale
Standard Deviation 0.2
EQ-5D-3L Score
3 Year
0.9 score on a scale
Standard Deviation 0.2
EQ-5D-3L Score
5 Year
0.9 score on a scale
Standard Deviation 0.2
EQ-5D-3L Score
7 Year
0.9 score on a scale
Standard Deviation 0.2
EQ-5D-3L Score
10 Year
0.9 score on a scale
Standard Deviation 0.2

SECONDARY outcome

Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 Year

Population: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different

The EQ-5D-3L is a standardized instrument widely used to measure health status. It is a self-reported assessment about the patient's quality of life composed of two parts: a questionnaire and a visual analogue scale (VAS). The VAS is a vertical scale ranging from 100 ('The best health you can imagine') to 0 ('The worst health you can imagine') where the patient reports his/her current state of health. Higher scores mean a better outcome.

Outcome measures

Outcome measures
Measure
Patients Who Received the Allofit IT With HXPE
n=194 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
EQ-5D VAS
Pre-Op
52.7 score on a scale
Standard Deviation 21.2
EQ-5D VAS
6 months
73.1 score on a scale
Standard Deviation 19.7
EQ-5D VAS
1 Year
78.4 score on a scale
Standard Deviation 16.6
EQ-5D VAS
2 Year
82.3 score on a scale
Standard Deviation 13.6
EQ-5D VAS
3 Year
82.1 score on a scale
Standard Deviation 14.1
EQ-5D VAS
5 Year
83.2 score on a scale
Standard Deviation 16.3
EQ-5D VAS
7 Year
81.9 score on a scale
Standard Deviation 14.5
EQ-5D VAS
10 Year
78.6 score on a scale
Standard Deviation 16.8

SECONDARY outcome

Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 Year

Population: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different.

The Oxford Hip Score (OHS) is a patient-reported outcome measure that was developed to specifically assess the patient's perspective of outcome following THA. The OHS consists of twelve questions covering function and pain associated with the hip. To calculate the total score, each response is scored from 0 (worst outcome) to 4 (best outcome) and the sum of all 12 items is reported with a maximum of 48, representing the best score possible. The outcome score can be categorized as Excellent: \> 41; Good: 34 - 41; Fair: 27 - 33; Poor: \< 27. Higher scores mean a better outcome.

Outcome measures

Outcome measures
Measure
Patients Who Received the Allofit IT With HXPE
n=194 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
Oxford Hip Score
Pre-Op
21.4 score on a scale
Standard Deviation 7.4
Oxford Hip Score
6 months
41.1 score on a scale
Standard Deviation 7.4
Oxford Hip Score
1 Year
43.2 score on a scale
Standard Deviation 6.4
Oxford Hip Score
2 Year
44.8 score on a scale
Standard Deviation 6.1
Oxford Hip Score
3 Year
45.1 score on a scale
Standard Deviation 5.4
Oxford Hip Score
5 Year
45.5 score on a scale
Standard Deviation 5.3
Oxford Hip Score
7 Year
44.8 score on a scale
Standard Deviation 6.7
Oxford Hip Score
10 Year
45.5 score on a scale
Standard Deviation 4.5

SECONDARY outcome

Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 Year

Population: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different.

The case administered University of California at Los Angeles (UCLA) score allows assessment of the case's activity level at each time point with scores from 1 (Wholly inactive: dependent on others; cannot leave residence) to 10 (Regularly participates in impact sports). Higher scores mean a better outcome

Outcome measures

Outcome measures
Measure
Patients Who Received the Allofit IT With HXPE
n=194 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
UCLA Activity Score
Pre-Op
4.3 score on a scale
Standard Deviation 1.7
UCLA Activity Score
6 months
5.8 score on a scale
Standard Deviation 1.8
UCLA Activity Score
1 Year
6.0 score on a scale
Standard Deviation 1.7
UCLA Activity Score
2 Year
6.7 score on a scale
Standard Deviation 1.3
UCLA Activity Score
3 Year
6.7 score on a scale
Standard Deviation 1.5
UCLA Activity Score
5 Year
6.7 score on a scale
Standard Deviation 1.7
UCLA Activity Score
7 Year
6.6 score on a scale
Standard Deviation 1.9
UCLA Activity Score
10 Year
6.5 score on a scale
Standard Deviation 1.8

SECONDARY outcome

Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 Year

Population: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different.

X-rays evaluated for radiolucencies, osteolysis, hypertrophy, subsidence,heterotopic ossification, etc

Outcome measures

Outcome measures
Measure
Patients Who Received the Allofit IT With HXPE
n=196 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
Radiographic Evaluations - Acetabular Site
3 Year · Radiolucency
1 Participants
Radiographic Evaluations - Acetabular Site
3 Year · None
131 Participants
Radiographic Evaluations - Acetabular Site
3 Year · Screw breakage
0 Participants
Radiographic Evaluations - Acetabular Site
5 Year · Bone Condensation
1 Participants
Radiographic Evaluations - Acetabular Site
5 Year · Cup migration
0 Participants
Radiographic Evaluations - Acetabular Site
5 Year · Osteolysis
1 Participants
Radiographic Evaluations - Acetabular Site
5 Year · Radiolucency
0 Participants
Radiographic Evaluations - Acetabular Site
5 Year · None
108 Participants
Radiographic Evaluations - Acetabular Site
5 Year · Screw breakage
0 Participants
Radiographic Evaluations - Acetabular Site
7 Year · Bone Condensation
0 Participants
Radiographic Evaluations - Acetabular Site
7 Year · Cup migration
0 Participants
Radiographic Evaluations - Acetabular Site
7 Year · Osteolysis
0 Participants
Radiographic Evaluations - Acetabular Site
7 Year · Radiolucency
0 Participants
Radiographic Evaluations - Acetabular Site
7 Year · None
96 Participants
Radiographic Evaluations - Acetabular Site
7 Year · Screw breakage
0 Participants
Radiographic Evaluations - Acetabular Site
10 Year · Bone Condensation
0 Participants
Radiographic Evaluations - Acetabular Site
10 Year · Cup migration
0 Participants
Radiographic Evaluations - Acetabular Site
10 Year · Osteolysis
0 Participants
Radiographic Evaluations - Acetabular Site
10 Year · Radiolucency
0 Participants
Radiographic Evaluations - Acetabular Site
10 Year · None
94 Participants
Radiographic Evaluations - Acetabular Site
10 Year · Screw breakage
0 Participants
Radiographic Evaluations - Acetabular Site
1 Year · Radiolucency
1 Participants
Radiographic Evaluations - Acetabular Site
1 Year · None
171 Participants
Radiographic Evaluations - Acetabular Site
1 Year · Screw breakage
0 Participants
Radiographic Evaluations - Acetabular Site
2 Year · Bone Condensation
1 Participants
Radiographic Evaluations - Acetabular Site
2 Year · Cup migration
0 Participants
Radiographic Evaluations - Acetabular Site
2 Year · Osteolysis
0 Participants
Radiographic Evaluations - Acetabular Site
2 Year · Radiolucency
0 Participants
Radiographic Evaluations - Acetabular Site
2 Year · None
123 Participants
Radiographic Evaluations - Acetabular Site
2 Year · Screw breakage
0 Participants
Radiographic Evaluations - Acetabular Site
3 Year · Bone Condensation
1 Participants
Radiographic Evaluations - Acetabular Site
3 Year · Cup migration
0 Participants
Radiographic Evaluations - Acetabular Site
3 Year · Osteolysis
0 Participants
Radiographic Evaluations - Acetabular Site
6 Months · None
175 Participants
Radiographic Evaluations - Acetabular Site
6 Months · Screw breakage
0 Participants
Radiographic Evaluations - Acetabular Site
1 Year · Bone Condensation
1 Participants
Radiographic Evaluations - Acetabular Site
1 Year · Cup migration
1 Participants
Radiographic Evaluations - Acetabular Site
1 Year · Osteolysis
0 Participants
Radiographic Evaluations - Acetabular Site
Immediat PostOp · Bone Condensation
0 Participants
Radiographic Evaluations - Acetabular Site
Immediat PostOp · Cup migration
1 Participants
Radiographic Evaluations - Acetabular Site
Immediat PostOp · Osteolysis
0 Participants
Radiographic Evaluations - Acetabular Site
Immediat PostOp · Radiolucency
6 Participants
Radiographic Evaluations - Acetabular Site
Immediat PostOp · None
188 Participants
Radiographic Evaluations - Acetabular Site
Immediat PostOp · Screw breakage
1 Participants
Radiographic Evaluations - Acetabular Site
6 Months · Bone Condensation
0 Participants
Radiographic Evaluations - Acetabular Site
6 Months · Cup migration
0 Participants
Radiographic Evaluations - Acetabular Site
6 Months · Osteolysis
0 Participants
Radiographic Evaluations - Acetabular Site
6 Months · Radiolucency
3 Participants

SECONDARY outcome

Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 Year

Population: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different.

X-rays evaluated for radiolucencies, osteolysis, hypertrophy, subsidence,heterotopic ossification, etc

Outcome measures

Outcome measures
Measure
Patients Who Received the Allofit IT With HXPE
n=196 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
Radiographic Evaluations - Femoral Side
Immediat PostOp · Stem Shift
0 Participants
Radiographic Evaluations - Femoral Side
Immediat PostOp · Stem Subsidence Subsidence
6 Participants
Radiographic Evaluations - Femoral Side
Immediat PostOp · Calcar rounding
5 Participants
Radiographic Evaluations - Femoral Side
Immediat PostOp · Calcar resorption
3 Participants
Radiographic Evaluations - Femoral Side
Immediat PostOp · Abnormalities
0 Participants
Radiographic Evaluations - Femoral Side
Immediat PostOp · Heterotopic Ossification
0 Participants
Radiographic Evaluations - Femoral Side
Immediat PostOp · AP- View: Radiolucency
1 Participants
Radiographic Evaluations - Femoral Side
Immediat PostOp · AP- View: Osteolysis
0 Participants
Radiographic Evaluations - Femoral Side
Immediat PostOp · Lateral - View: Radiolucency
0 Participants
Radiographic Evaluations - Femoral Side
Immediat PostOp · Lateral - View: Osteolysis
1 Participants
Radiographic Evaluations - Femoral Side
Immediat PostOp · None
180 Participants
Radiographic Evaluations - Femoral Side
6 Months · Stem Shift
1 Participants
Radiographic Evaluations - Femoral Side
6 Months · Stem Subsidence Subsidence
6 Participants
Radiographic Evaluations - Femoral Side
6 Months · Calcar rounding
55 Participants
Radiographic Evaluations - Femoral Side
6 Months · Calcar resorption
5 Participants
Radiographic Evaluations - Femoral Side
6 Months · Abnormalities
1 Participants
Radiographic Evaluations - Femoral Side
6 Months · Heterotopic Ossification
3 Participants
Radiographic Evaluations - Femoral Side
6 Months · AP- View: Radiolucency
2 Participants
Radiographic Evaluations - Femoral Side
6 Months · AP- View: Osteolysis
2 Participants
Radiographic Evaluations - Femoral Side
6 Months · Lateral - View: Radiolucency
0 Participants
Radiographic Evaluations - Femoral Side
6 Months · Lateral - View: Osteolysis
1 Participants
Radiographic Evaluations - Femoral Side
6 Months · None
103 Participants
Radiographic Evaluations - Femoral Side
1 Year · Stem Shift
3 Participants
Radiographic Evaluations - Femoral Side
1 Year · Stem Subsidence Subsidence
4 Participants
Radiographic Evaluations - Femoral Side
1 Year · Calcar rounding
68 Participants
Radiographic Evaluations - Femoral Side
1 Year · Calcar resorption
5 Participants
Radiographic Evaluations - Femoral Side
1 Year · Abnormalities
0 Participants
Radiographic Evaluations - Femoral Side
1 Year · Heterotopic Ossification
2 Participants
Radiographic Evaluations - Femoral Side
1 Year · AP- View: Radiolucency
6 Participants
Radiographic Evaluations - Femoral Side
1 Year · AP- View: Osteolysis
1 Participants
Radiographic Evaluations - Femoral Side
1 Year · Lateral - View: Radiolucency
0 Participants
Radiographic Evaluations - Femoral Side
1 Year · Lateral - View: Osteolysis
2 Participants
Radiographic Evaluations - Femoral Side
1 Year · None
83 Participants
Radiographic Evaluations - Femoral Side
2 Year · Stem Shift
1 Participants
Radiographic Evaluations - Femoral Side
2 Year · Stem Subsidence Subsidence
0 Participants
Radiographic Evaluations - Femoral Side
2 Year · Calcar rounding
62 Participants
Radiographic Evaluations - Femoral Side
2 Year · Calcar resorption
2 Participants
Radiographic Evaluations - Femoral Side
2 Year · Abnormalities
0 Participants
Radiographic Evaluations - Femoral Side
2 Year · Heterotopic Ossification
1 Participants
Radiographic Evaluations - Femoral Side
2 Year · AP- View: Radiolucency
5 Participants
Radiographic Evaluations - Femoral Side
2 Year · AP- View: Osteolysis
0 Participants
Radiographic Evaluations - Femoral Side
2 Year · Lateral - View: Radiolucency
1 Participants
Radiographic Evaluations - Femoral Side
2 Year · Lateral - View: Osteolysis
0 Participants
Radiographic Evaluations - Femoral Side
2 Year · None
52 Participants
Radiographic Evaluations - Femoral Side
3 Year · Stem Shift
1 Participants
Radiographic Evaluations - Femoral Side
3 Year · Stem Subsidence Subsidence
0 Participants
Radiographic Evaluations - Femoral Side
3 Year · Calcar rounding
56 Participants
Radiographic Evaluations - Femoral Side
3 Year · Calcar resorption
1 Participants
Radiographic Evaluations - Femoral Side
3 Year · Abnormalities
0 Participants
Radiographic Evaluations - Femoral Side
3 Year · Heterotopic Ossification
4 Participants
Radiographic Evaluations - Femoral Side
3 Year · AP- View: Radiolucency
5 Participants
Radiographic Evaluations - Femoral Side
3 Year · AP- View: Osteolysis
1 Participants
Radiographic Evaluations - Femoral Side
3 Year · Lateral - View: Radiolucency
3 Participants
Radiographic Evaluations - Femoral Side
3 Year · Lateral - View: Osteolysis
1 Participants
Radiographic Evaluations - Femoral Side
3 Year · None
61 Participants
Radiographic Evaluations - Femoral Side
5 Year · Stem Shift
1 Participants
Radiographic Evaluations - Femoral Side
5 Year · Stem Subsidence Subsidence
0 Participants
Radiographic Evaluations - Femoral Side
5 Year · Calcar rounding
50 Participants
Radiographic Evaluations - Femoral Side
5 Year · Calcar resorption
3 Participants
Radiographic Evaluations - Femoral Side
5 Year · Abnormalities
0 Participants
Radiographic Evaluations - Femoral Side
5 Year · Heterotopic Ossification
4 Participants
Radiographic Evaluations - Femoral Side
5 Year · AP- View: Radiolucency
6 Participants
Radiographic Evaluations - Femoral Side
5 Year · AP- View: Osteolysis
1 Participants
Radiographic Evaluations - Femoral Side
5 Year · Lateral - View: Radiolucency
1 Participants
Radiographic Evaluations - Femoral Side
5 Year · Lateral - View: Osteolysis
1 Participants
Radiographic Evaluations - Femoral Side
5 Year · None
43 Participants
Radiographic Evaluations - Femoral Side
7 Year · Stem Shift
0 Participants
Radiographic Evaluations - Femoral Side
7 Year · Stem Subsidence Subsidence
0 Participants
Radiographic Evaluations - Femoral Side
7 Year · Calcar rounding
52 Participants
Radiographic Evaluations - Femoral Side
7 Year · Calcar resorption
1 Participants
Radiographic Evaluations - Femoral Side
7 Year · Abnormalities
1 Participants
Radiographic Evaluations - Femoral Side
7 Year · Heterotopic Ossification
5 Participants
Radiographic Evaluations - Femoral Side
7 Year · AP- View: Radiolucency
6 Participants
Radiographic Evaluations - Femoral Side
7 Year · AP- View: Osteolysis
1 Participants
Radiographic Evaluations - Femoral Side
7 Year · Lateral - View: Radiolucency
0 Participants
Radiographic Evaluations - Femoral Side
7 Year · Lateral - View: Osteolysis
0 Participants
Radiographic Evaluations - Femoral Side
7 Year · None
30 Participants
Radiographic Evaluations - Femoral Side
10 Year · Stem Shift
0 Participants
Radiographic Evaluations - Femoral Side
10 Year · Stem Subsidence Subsidence
0 Participants
Radiographic Evaluations - Femoral Side
10 Year · Calcar rounding
45 Participants
Radiographic Evaluations - Femoral Side
10 Year · Heterotopic Ossification
3 Participants
Radiographic Evaluations - Femoral Side
10 Year · AP- View: Radiolucency
5 Participants
Radiographic Evaluations - Femoral Side
10 Year · AP- View: Osteolysis
2 Participants
Radiographic Evaluations - Femoral Side
10 Year · Lateral - View: Radiolucency
1 Participants
Radiographic Evaluations - Femoral Side
10 Year · Lateral - View: Osteolysis
2 Participants
Radiographic Evaluations - Femoral Side
10 Year · None
34 Participants
Radiographic Evaluations - Femoral Side
10 Year · Calcar resorption
2 Participants
Radiographic Evaluations - Femoral Side
10 Year · Abnormalities
0 Participants

Adverse Events

Patients Who Received the Allofit IT With HXPE

Serious events: 52 serious events
Other events: 25 other events
Deaths: 13 deaths

Serious adverse events

Serious adverse events
Measure
Patients Who Received the Allofit IT With HXPE
n=197 participants at risk
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
Cardiac disorders
General
4.1%
8/197 • Number of events 13 • 10 years post-surgery
Same definitions
Renal and urinary disorders
General
0.51%
1/197 • Number of events 1 • 10 years post-surgery
Same definitions
Infections and infestations
General
0.51%
1/197 • Number of events 1 • 10 years post-surgery
Same definitions
Musculoskeletal and connective tissue disorders
General
8.6%
17/197 • Number of events 18 • 10 years post-surgery
Same definitions
Nervous system disorders
General
0.51%
1/197 • Number of events 2 • 10 years post-surgery
Same definitions
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
General
3.6%
7/197 • Number of events 8 • 10 years post-surgery
Same definitions
Respiratory, thoracic and mediastinal disorders
General
1.0%
2/197 • Number of events 3 • 10 years post-surgery
Same definitions
General disorders
General
5.1%
10/197 • Number of events 13 • 10 years post-surgery
Same definitions
Product Issues
Hip Related
1.5%
3/197 • Number of events 5 • 10 years post-surgery
Same definitions

Other adverse events

Other adverse events
Measure
Patients Who Received the Allofit IT With HXPE
n=197 participants at risk
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
Gastrointestinal disorders
General Complications - Adverse Events
1.0%
2/197 • Number of events 4 • 10 years post-surgery
Same definitions
Musculoskeletal and connective tissue disorders
General Complications - Adverse Events
4.1%
8/197 • Number of events 17 • 10 years post-surgery
Same definitions
General disorders
General Complications - Adverse Events
1.5%
3/197 • Number of events 13 • 10 years post-surgery
Same definitions
Product Issues
Hip Related Complications - Adverse Events
2.0%
4/197 • Number of events 8 • 10 years post-surgery
Same definitions
Vascular disorders
Hip Related Complications - Adverse Events
1.5%
3/197 • Number of events 3 • 10 years post-surgery
Same definitions
General disorders
Hip Related Complications - Adverse Events
1.5%
3/197 • Number of events 3 • 10 years post-surgery
Same definitions

Additional Information

Georgia Tsapara

Zimmer Biomet

Phone: +41 79 94 54936

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place